来自官方财务报表的收入、利润与现金流历史。
DaVita Inc.为美国慢性肾衰竭患者提供肾透析服务。该公司经营肾透析中心，并在门诊透析中心提供相关实验室服务。它还提供门诊、医院住院和家庭血液透析透析服务；运营临床实验室，为终末期肾病患者提供透析常规实验室测试和其他医生规定的实验室测试；以及门诊透析中心的管理和行政服务。此外，该公司还通过基于风险的综合护理安排和其他综合护理安排为患者提供综合护理和疾病管理服务；临床研究计划；医生服务；和全面的肾脏护理服务。此外，它还从事移植软件业务。该公司前身为 DaVita HealthCare Partners Inc.，于 2016 年 9 月更名为 DaVita Inc.。DaVita Inc. 成立于 1994 年，总部位于科罗拉多州丹佛市。
机器翻译
| 利润表 | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $13.8B | $13.6B | $12.8B | $12.1B | $11.6B | $11.6B | $11.6B | $11.4B | $11.4B | $10.9B | $14.7B | $13.8B | $12.8B | $11.8B | $8.2B | $6.8B | $6.4B | $6.1B | $5.7B | $5.3B | $4.9B |
| 毛利 | $4.3B | $3.7B | $4.2B | $3.8B | $3.4B | $3.6B | $3.6B | $3.5B | $3.2B | $3.2B | $3.3B | $3.1B | $3.7B | $3.6B | $2.6B | $2.1B | $1.8B | $1.9B | $1.7B | $1.7B | $1.5B |
| 毛利率% | 31.1% | 27.0% | 32.9% | 31.5% | 29.3% | 31.4% | 30.8% | 30.5% | 28.1% | 29.8% | 22.2% | 22.7% | 28.7% | 30.3% | 31.8% | 30.9% | 27.8% | 30.4% | 30.7% | 31.8% | 30.5% |
| 营业利润（EBIT） | $2.1B | $2.0B | $2.1B | $1.6B | $1.3B | $1.8B | $1.7B | $1.6B | $1.5B | $1.8B | $2.0B | $1.1B | $1.8B | $1.6B | $1.3B | $1.2B | $994M | $940M | $869M | $862M | $739M |
| 营业利润率% | 15.0% | 14.7% | 16.3% | 13.2% | 11.5% | 15.5% | 14.7% | 14.4% | 13.4% | 16.7% | 13.8% | 8.2% | 14.2% | 13.2% | 15.8% | 17.0% | 15.4% | 15.4% | 15.3% | 16.4% | 15.2% |
| 净利 | $781M | $747M | $936M | $692M | $560M | $978M | $774M | $811M | $159M | $664M | $880M | $270M | $723M | $633M | $536M | $478M | $406M | $423M | $374M | $382M | $290M |
| 净利润率 % | 5.7% | 5.5% | 7.3% | 5.7% | 4.8% | 8.4% | 6.7% | 7.1% | 1.4% | 6.1% | 6.0% | 2.0% | 5.7% | 5.4% | 6.6% | 7.0% | 6.3% | 6.9% | 6.6% | 7.2% | 5.9% |
| EBITDA | $2.7B | $2.6B | $2.7B | $2.3B | $2.1B | $2.5B | $2.3B | $2.3B | $2.1B | $2.6B | $2.8B | $1.7B | $2.3B | $2.1B | $1.6B | $1.4B | $1.2B | $1.2B | $1.1B | $1.1B | $913M |
| 每股收益（EPS） | $10.14 | $8.48 | $10.73 | $7.42 | $5.85 | $8.90 | $6.31 | $5.27 | $0.92 | $3.47 | $4.29 | $1.25 | $3.33 | $2.95 | $2.74 | $2.48 | $1.97 | $2.03 | $1.77 | $1.78 | $1.37 |
| 已发行股数 (M) | 69M | 88M | 87M | 93M | 96M | 110M | 123M | 154M | 172M | 191M | 205M | 216M | 217M | 215M | 196M | 193M | 206M | 208M | 212M | 215M | 212M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 DVA 交互式查看器。 /companies/us/DVA
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms